Johnson & Johnson's Tremfya is the first IL-23 inhibitor to gain FDA approval in a paediatric population for plaque psoriasis ...
China’s National Medical Products Administration (NMPA) has granted approval for four-weekly intravenous (IV) maintenance ...
Oral liquid drugs play a vital role for patients who have difficulty swallowing tablets and for those requiring personalised ...
Genmab has signed an agreement to buy all shares of Merus at $97 per share, in an all-cash transaction valued at $8bn.
More than two-thirds – 67% - of first responders organisations have deployed new cybersecurity protections in the last 12 ...
How to build flexibility into your CGT manufacturing process while maintaining regulatory compliance
MasterControl research shows 40% of advanced therapy executives aren't confident they can meet CGT demand over the next three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback